Exchange: NASDAQ·Updated 07:30 PM EST
INGN logo

INGN Inogen Inc

$5.63
$0.06
(1.05%)
Today
Closed $5.63
$0.00
(0.00%)
After Hours
Reported EarningsNov 5
Mkt Cap$147.95M
Vol238,534.00

About INGN

Inogen, Inc. is a global medical technology company offering innovative respiratory products for use in the homecare setting. It supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Beverly, MA.
47

Neutral Sentiment

How do you feel about INGN?

StocktwitsEarnings
$INGN Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.02 down -150.00% YoY • Reported revenue of $77.19M down -16.45% YoY • Inogen expects fourth-quarter 2026 continuing-operations revenue of $65M to $68M, full-year 2026 continuing-operations revenue of $298M to $301M, and adjusted full-year loss of $7M to $8M.
LALC_Capital
$INGN update on our Oct 12 report on Inogen. COO Andy Reding took over as CEO from Kevin Smith on Oct 30. The US oxygen rental business closed its sale to Rotech on Nov 2 for up to about 24.8M, paid in six installments, and the board approved a cost program aimed at about 20M a year of savings, about half of it in Q4 and the rest through 2027. Q3 revenue from continuing operations was 77.2M, down 2.4%: US sales up 3.8%, international down 9.0%. The operating loss was 15.6M vs 5.4M a year ago. Cash and securities 97.7M, no debt. Can the US business carry growth while international shrinks? Filing: https://www.sec.gov/Archives/edgar/data/1294133/000129413326000040/0001294133-26-000040-index.htm

Advertisement|Remove ads.